iMcKesson, the e-health business launched with much fanfare by McKesson/HBOC less than a year ago, has met with a swift end. McKesson/HBOC plans to fold the unit’s physician and transaction processing services into its information technologies
iMcKesson, the e-health business launched with much fanfare by McKesson/HBOC less than a year ago, has met with a swift end. McKesson/HBOC plans to fold the unit’s physician and transaction processing services into its information technologies division and drop the iMcKesson name. The company attributes the sudden restructuring to changes in market conditions. iMcKesson CEO David Mahoney, who was also co-CEO of McKesson/HBOC, plans to leave the company. John Hammergren, chair of the board, is now president and CEO of McKesson/HBOC. iMcKesson lost $124 million in the first nine months of the current fiscal year, although $95 million of that was attributed to write-offs on investments such as WebMD.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.